|
1
|
Hampel H, Frankel WL, Martin E, et al:
Screening for the Lynch syndrome (hereditary nonpolyposis
colorectal cancer). N Engl J Med. 352:1851–1860. 2005.
|
|
2
|
Gryfe R, Kim H, Hsieh ET, et al: Tumor
microsatellite instability and clinical outcome in young patients
with colorectal cancer. N Engl J Med. 342:69–77. 2000.
|
|
3
|
Greenson JK, Bonner JD, Ben-Yzhak O, et
al: Phenotype of microsatellite unstable colorectal carcinomas:
Well-differentiated and focally mucinous tumors and the absence of
dirty necrosis correlate with microsatellite instability. Am J Surg
Pathol. 27:563–570. 2003.
|
|
4
|
Greenson JK, Huang SC, Herron C, et al:
Pathologic predictors of microsatellite instability in colorectal
cancer. Am J Surg Pathol. 33:126–133. 2009.
|
|
5
|
Duval A and Hamelin R: Mutations at coding
repeat sequences in mismatch repair-deficient human cancers: toward
a new concept of target genes for instability. Cancer Res.
62:2447–2454. 2002.
|
|
6
|
Wang HC, Liu CS, Chiu CF, et al:
Significant association of DNA repair gene Ku80 genotypes with
breast cancer susceptibility in Taiwan. Anticancer Res.
29:5251–5254. 2009.
|
|
7
|
Jones NJ, Zhao Y, Siciliano MJ and
Thompson LH: Assignment of the XRCC2 human DNA repair gene to
chromosome 7q36 by complementation analysis. Genomics. 26:619–622.
1995.
|
|
8
|
Thacker J, Tambini CE, Simpson PJ, Tsui LC
and Scherer SW: Localization to chromosome 7q36.1 of the human
XRCC2 gene, determining sensitivity to DNA-damaging agents. Hum Mol
Genet. 4:113–120. 1995.
|
|
9
|
Liu N, Lamerdin JE, Tebbs RS, et al: XRCC2
and XRCC3, new human Rad51-family members, promote chromosome
stability and protect against DNA cross-links and other damages.
Mol Cell. 1:783–793. 1998.
|
|
10
|
Rafii S, O’Regan P, Xinarianos G, et al: A
potential role for the XRCC2 R188H polymorphic site in DNA-damage
repair and breast cancer. Hum Mol Genet. 11:1433–1438. 2002.
|
|
11
|
Wang R, Wang W and Zhang JW: Correlation
between XRCC2 and XRCC5 single nucleotide polymorphisms and
drug-sensitivity of human lung cancer cells. Zhonghua Yi Xue Za
Zhi. 88:3059–3062. 2008.(In Chinese).
|
|
12
|
Romanowicz-Makowska H, Smolarz B, Połać I
and Sporny S: Single nucleotide polymorphisms of RAD51 G135C, XRCC2
Arg188His and XRCC3 Thr241Met homologous recombination repair genes
and the risk of sporadic endometrial cancer in Polish women. J
Obstet Gynaecol Res. 38:918–924. 2012.
|
|
13
|
Han J, Hankinson SE, Hunter DJ and De Vivo
I: Genetic variations in XRCC2 and XRCC3 are not associated with
endometrial cancer risk. Cancer Epidemiol Biomarkers Prev.
13:330–331. 2004.
|
|
14
|
Lin WY, Camp NJ, Cannon-Albright LA, et
al: A role for XRCC2 gene polymorphisms in breast cancer risk and
survival. J Med Genet. 48:477–484. 2011.
|
|
15
|
Yen CY, Liu SY, Chen CH, et al:
Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2,
XRCC3, and XRCC4 and their association with oral cancer in Taiwan.
J Oral Pathol Med. 37:271–277. 2008.
|
|
16
|
Curtin K, Lin WY, George R, et al: Genetic
variants in XRCC2: new insights into colorectal cancer
tumorigenesis. Cancer Epidemiol Biomarkers Prev. 18:2476–2484.
2009.
|
|
17
|
Krupa R, Sliwinski T,
Wisniewska-Jarosinska M, et al: Polymorphisms in RAD51, XRCC2 and
XRCC3 genes of the homologous recombination repair in colorectal
cancer - a case control study. Mol Biol Rep. 38:2849–2854.
2011.
|
|
18
|
Hoeijmakers JH: DNA damage, aging, and
cancer. N Engl J Med. 361:1475–1485. 2009.
|
|
19
|
Farmer H, McCabe N, Lord CJ, et al:
Targeting the DNA repair defect in BRCA mutant cells as a
therapeutic strategy. Nature. 434:917–921. 2005.
|
|
20
|
Whitehurst AW, Bodemann BO, Cardenas J, et
al: Synthetic lethal screen identification of chemosensitizer loci
in cancer cells. Nature. 446:815–819. 2007.
|
|
21
|
Vilar E, Bartnik CM, Stenzel SL, et al:
MRE11 deficiency increases sensitivity to poly(ADP-ribose)
polymerase inhibition in microsatellite unstable colorectal
cancers. Cancer Res. 71:2632–2642. 2011.
|
|
22
|
O’Connor MJ, Martin NM and Smith GC:
Targeted cancer therapies based on the inhibition of DNA strand
break repair. Oncogene. 26:7816–7824. 2007.
|
|
23
|
Fong PC, Boss DS, Yap TA, et al:
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers. N Engl J Med. 361:123–134. 2009.
|
|
24
|
Calabrese CR, Batey MA, Thomas HD, et al:
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1
inhibitors: chemopotentiation and pharmacological studies. Clin
Cancer Res. 9:2711–2718. 2003.
|
